Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437176 | 0.95 | MDM2 (0.90) | MDM2NOTUMKMORPA1RIPK1 | |
| SCHEMBL9893643 | 0.94 | MDM2 (0.88) | MDM2NOTUMKMORPA1RIPK1 | |
| SCHEMBL28796347 | 0.93 | MDM2 (0.88) | MDM2NOTUMKMORPA1RIPK1 | |
| SCHEMBL1437130 | 0.93 | MDM2 (0.86) | MDM2NOTUMKMORPA1HTR2A | |
| SCHEMBL9894128 | 0.92 | MDM2 (0.85) | MDM2NOTUMKMORIPK1HTR2A | |
| SCHEMBL1443240 | 0.92 | MDM2 (1.00) | MDM2NOTUMKMORIPK1HTR2A | |
| SCHEMBL28796349 | 0.91 | MDM2 (0.83) | MDM2NOTUMKMORIPK1HTR2A | |
| SCHEMBL1437215 | 0.90 | MDM2 (0.81) | MDM2NOTUMKMORPA1RIPK1 | |
| SCHEMBL9893721 | 0.89 | MDM2 (0.80) | MDM2NOTUMRIPK1HTR2AHTR2C | |
| SCHEMBL1437096 | 0.89 | MDM2 (0.79) | MDM2NOTUMKMORPA1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NOTUM 4675/4885KMO 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.